Stocktoria

PFIZER INC PFE

NYSE · stock · Pharmaceutical Preparations · website · IPO 1944-01-17 · LEI

PFIZER INC (PFE) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $62.6B at a 12.4% net margin.

Chart by TradingView
46/100
Stocktoria Quality Score · grade C
4/9
Piotroski F — financial health
Altman Z″ — distress risk
Dividend yield · no dividend
-2.52
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
5 5 5 4 6 7 5 4 8 4 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$26.31 as of 2026-08-01 · +6.3% 1y
$24.08$28.0852-wk

Beneish M-score: -2.52 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$138.4B
P / E17.8×
Net margin 5y avg17.3%
Return on equity 5y avg16.3%
Beta0.28
Employees75,000

Analyst price target

$28.64 +8.9% vs last
consensus: buy · 26 analysts
target range $25.00 – $35.75 · median $28.00
2 strong buy · 8 buy · 16 hold · 1 sell · 1 strong sell
Recent analyst actions
DateFirmRating
2026-08-07GuggenheimBuy (main)
2026-07-13BMO CapitalOutperform (main)
2026-07-13GuggenheimBuy (main)
2026-07-10B of A SecuritiesNeutral (main)
2026-07-08JP MorganNeutral (main)
2026-07-06Cantor FitzgeraldNeutral (reit)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Forward estimates · earnings calendar →

Forward EPS est.$2.89
Forward P / E9.1×

Consensus analyst estimates and scheduled dates — forward-looking, may change.

Smart money · insiders, last 12 months

Insiders net sold -$51,400 on the open market · 1 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 45%
Net marginstronger than 83%
Return on equitystronger than 73%
Revenue growthstronger than 30%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 4/9 tests passed

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
PFEPFIZER INC4/917.8-1.6%
ABBVAbbVie Inc.7/9-0.34105.9+8.6%
MRKMerck & Co., Inc.4/917.4+1.3%
LLYELI LILLY & Co7/955.1+44.7%
BMYBRISTOL MYERS SQUIBB CO7/916.7-0.2%
ABTABBOTT LABORATORIES5/94.8525.1+5.7%
JNJJOHNSON & JOHNSON4/922.9+6%

All Manufacturing companies →

About PFIZER INC

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

FAQ

Is PFE financially healthy?

PFIZER INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).

Does PFE pay a dividend?

No, PFIZER INC does not currently pay a dividend.

How profitable is PFE?

In FY2025, PFIZER INC had a net margin of 12.4% and a return on equity of 9.0%.

Is PFE overvalued or undervalued?

PFIZER INC trades at about 19.3× trailing earnings — near its 10-year norm (10-year range 8.1×–73.2×, median 19.4×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for PFE?

The average Wall-Street price target for PFIZER INC is $28.64, about 8.9% above the recent price, from 26 analysts (consensus: buy).

Is PFE a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on PFIZER INC: a Piotroski F-score of 4/9, a P/E of about 17.8×. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.